Modulators of cystic fibrosis transmembrane conductance regulator

• Main Authors: ANDERSON CHARLES, BINCH HAYLEY MARIE, MCCARTNEY JASON, JOSHI PRAMOD VIRUPAX, PIERRE FABRICE JEAN DENIS, KHATUYA HARIPADA, LIN CHIAING, MARELIUS GULIN ERDOGAN, UY JOHNNY, SILINA ALINA, ARUMUGAM VIJAYALAKSMI, GROSS RAYMOND STANLEY, KRENITSKY PAUL JOHN, CONROY ERICA, CHOW JERRY, COON TIMOTHY RICHARD, FRIEMAN BRYAN A, TERMIN ANDREAS P, NICHOLLS GEORGIA MCGAUGHEY, GROOTENHUIS PETER DIEDERIK JAN, HADIDA-RUAH SARA SABINA, MELILLO VITO, CLEVELAND THOMAS, BEAR BRIAN RICHARD, MILLER MARK THOMAS, CLEMENS JEREMY J
• Format: Patent
• Language: Chinese; English
• Published: 22.01.2021
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to modulators of a cystic fibrosis transmembrane conductance regulator. The present invention is characterized by compounds of formula (I): or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p and q are as defined herein, for use in the treatment of CFTR-mediated diseases such as cystic fibrosis. The invention is also characterized by pharmaceutical compositions, methods of treatment thereof, and kits. 本发明涉及囊性纤维化跨膜转导调节因子调节剂，本发明特征在于式(I)的化合物：或其药学上可接受的盐，其中R1、R2、R3、W、X、Y、Z、n、o、p和q如本文所定义，其用于治疗CFTR介导的疾病，例如囊性纤维化。本发明的特征还在于药物组合物，其治疗方法和试剂盒。